Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 16/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280500 | 0.96 | HTRA1 (0.33) | HTRA1 | |
| SCHEMBL14583634 | 0.94 | HTRA1 (0.31) | HTRA1 | |
| SCHEMBL13251678 | 0.91 | HTRA1 (0.36) | HTRA1 | |
| SCHEMBL7857572 | 0.90 | CTSL (0.38) | HTRA1 | |
| SCHEMBL14598540 | 0.90 | CTSL (0.38) | HTRA1 | |
| SCHEMBL13251684 | 0.90 | HTRA1 (0.31) | HTRA1 | |
| SCHEMBL13251683 | 0.86 | CTSL (0.33) | — | |
| SCHEMBL16316610 | 0.85 | MMP1 (0.34) | HTRA1 | |
| SCHEMBL16301584 | 0.85 | MMP1 (0.34) | HTRA1 | |
| SCHEMBL8282361 | 0.82 | NR1I2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7192957-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192957-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | HTRA1 22/4885 |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | HAVCR2, ENPEP, SERPINB1 | HTRA1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.